Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Albarrán, Víctor, Chamorro, Jesús, Pozas, Javier, San Román, María, Rosero, Diana Isabel, Saavedra, Cristina, Gion, María, Cortés, Alfonso, Escalera, Elena, Guerra, Eva, López Miranda, Elena, Fernández Abad, María, Martínez Jañez, Noelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196382/
https://www.ncbi.nlm.nih.gov/pubmed/37213307
http://dx.doi.org/10.3389/fonc.2023.1158981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196382/
https://www.ncbi.nlm.nih.gov/pubmed/37213307
http://dx.doi.org/10.3389/fonc.2023.1158981

Ejemplares similares